Tumor Biomarker Discovery

1. Front Matter

   Pages i-xi

   PDF

2. Identification of Tumor-Associated Antigens as Diagnostic and Predictive Biomarkers in Cancer

   • Jian-Ying Zhang, Kok Sun Looi, Eng M. Tan

   Pages 1-10

3. Autoantibodies Against Cancer Antigens

   • Sacha Gnjatic, Lloyd J. Old, Yao-Tseng Chen

   Pages 11-19

4. Discovery of Antibody Biomarkers Using Protein Microarrays of Tumor Antigens Cloned in High Throughput

   • Madhumita Chatterjee, Jerzy Wojciechowski, Michael A. Tainsky

   Pages 21-38

5. Analysis of Glycans on Serum Proteins Using Antibody Microarrays

   • Songming Chen, Brian B. Haab

   Pages 39-58

6. Glycoproteomic Analysis by Two-Dimensional Electrophoresis

   • Mary Ann Comunale, Anand Mehta

   Pages 59-74

7. All-Liquid Separations, Protein Microarrays, and Mass Spectrometry to Interrogate Serum Proteomes: An Application to Serum Glycoproteomics

   • Tasneem H. Patwa, Yinghua Qiu, Jia Zhao, Diane M. Simeone, David M. Lubman

   Pages 75-87

8. Reverse-Phase Protein Microarrays for Theranostics and Patient Tailored Therapy

   • Virginia Espina, Lance A. Liotta, Emanuel F. Petricoin III

   Pages 89-105

9. Serum Proteomics Using Mass Spectrometry

   • Brian L. Hood, David E. Malehorn, Thomas P. Conrads, William L. Bigbee

   Pages 107-128

10. Hormones as Biomarkers: Practical Guide to Utilizing Luminex Technologies for Biomarker Research

    • Faina Linkov, Zoya Yurkovetsky, Anna Lokshin

    Pages 129-141

11. High-Throughput Analysis of Serum Antigens Using Sandwich ELISAs on Microarrays

    • Shannon L. Servoss, Rachel Gonzalez, Susan Varnum, Richard C. Zangar

    Pages 143-150

12. Tissue Microarrays as a Tool in the Discovery and Validation of Tumor Markers

    • Stephen M. Hewitt

    Pages 151-161

13. Quantitative, Fluorescence-Based In-Situ Assessment of Protein Expression

    • Christopher B. Moeder, Jennifer M. Giltnane, Sharon Pozner Moulis, David L. Rimm

    Pages 163-175

14. Tumor Marker Discovery by Expression Profiling RNA from Formalin Fixed Paraffin Embedded Tissues

    • Maureen T. Cronin, Debjani Dutta, Mylan Pho, Anhthu Nguyen, Jennie Jeong, Mei-lan Liu

    Pages 177-193

15. High-Throughput Mutation Screening Using a Single Amplification Condition

    • Lijia Shi, John E. Landers

    Pages 195-204

16. DNA Sequencing of Cancer-Related Genes for Biomarker Discovery

    • Lisa M. Farwell, Victoria A. Joshi

    Pages 205-220

17. Analysis of Loss of Heterozygosity in Circulating DNA

    • Takeshi Nakamura, Eiji Sunami, Tuny Nguyen, Dave S.B. Hoon

    Pages 221-229

18. Pharmacogenomics

    • Shilong Zhong, Marjorie Romkes

    Pages 231-245

19. Study Designs in Genetic Epidemiology

    • Michele L. Cote

    Pages 247-257

20. Developing Classifiers for the Detection of Cancer Using Multi-Analytes

    • Adi Laurentiu Tarca, Sorin Draghici, Roberto Romero

    Pages 259-272

Biomarkers are molecular indicators of a biological status and, as biochemical species, can be interrogated to evaluate disease status and therapeutic interventions. Biomarkers may be detectable in the blood, other body fluids, or tissues. The expectation is that the level of an informative biomarker is related to the specific type of disease present in the body. Hence, disease-relevant biomarkers can be used to measure the presence, progress, or intensity of disease. Through a variety of mechanisms, cancer cells provide the biomarker material for their own detection. Tumor biomarkers include cancer-specific mutations or changes in gene expression, both of which can result in aberrant protein expression. These variant or abundant proteins can be detectable in the circulation as the free proteins or as novel autoantibodies to those proteins, the latter indicating that the immune system can provide an exquisitely sensitive sensor of disease. Because cancer cells shed DNA in the circu- tion, an event rarely seen in healthy individuals, tumor-specific genetic changes, such as promoter methylation or gene mutations, are detectable in DNA prepared from plasma or other body fluids. Cancer-related biochemical changes often effect measurable me- bolic variations within a cell or organism. In addition, these biochemical changes result in posttranslational modification of proteins via glycosylation or phosphorylation providing a plethora of opportunity for biomarker discovery.

• 2D liquid chromatography
• Antigen
• Biomarker analyte panels
• Cancer detection
• Human immune system
• Laboratory
• Magnetic resonance spectroscopy
• Mass spectroscopy
• Protein microarrays
• tissue

From the reviews: “This well-illustrated book is an excellent resource on nucleic acid and protein-based technologies and metabolic profiling by analytic means or mass spectroscopy as well as for study designs for tumor biomarker discovery and validation. The audience includes both researchers interested in the identification and development of new tumor biomarkers and clinicians who need to be familiar with these new technologies in order to … treat cancer patients. In addition to researchers and clinicians, students interested in tumor biomarkers will find this book extremely useful.” (Omer Iqbal, Doody’s Review Service, January, 2010)

• School of Medicine , Wayne State University, Detroit, U.S.A.

  Michael A. Tainsky

Policies and ethics